These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16730870)

  • 21. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.
    Stein DJ; Bouwer C; Hawkridge S; Emsley RA
    J Clin Psychiatry; 1997 Mar; 58(3):119-22. PubMed ID: 9108814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
    Tzavellas E; Karaiskos D; Ilias I; Liappas I; Paparrigopoulos T
    Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder.
    Hollander E; Dell'Osso B
    Int Clin Psychopharmacol; 2006 May; 21(3):189-91. PubMed ID: 16528143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial.
    Maraone A; Trebbastoni A; Di Vita A; D'Antonio F; De Lena C; Pasquini M
    JMIR Res Protoc; 2023 May; 12():e39223. PubMed ID: 37166948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The combined effects of memantine and fluoxetine on an animal model of obsessive compulsive disorder.
    Wald R; Dodman N; Shuster L
    Exp Clin Psychopharmacol; 2009 Jun; 17(3):191-7. PubMed ID: 19586234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Gamel NN
    J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Memantine for comorbid obsessive-compulsive disorder and Asperger disorder suggests a link in glutamatergic dysregulation.
    Bernhardt EB; Walsh KH; Posey DJ; McDougle CJ
    J Clin Psychopharmacol; 2011 Oct; 31(5):673-5. PubMed ID: 21881459
    [No Abstract]   [Full Text] [Related]  

  • 31. The use of memantine in neuropsychiatric disorders: An overview.
    Lu S; Nasrallah HA
    Ann Clin Psychiatry; 2018 Aug; 30(3):234-248. PubMed ID: 30028898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder.
    Oulis P; Mourikis I; Konstantakopoulos G
    Int Clin Psychopharmacol; 2011 Jul; 26(4):221-4. PubMed ID: 21460732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
    Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
    J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: A network meta-analysis.
    Zhou DD; Zhou XX; Li Y; Zhang KF; Lv Z; Chen XR; Wan LY; Wang W; Wang GM; Li DQ; Ai M; Kuang L
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 90():277-287. PubMed ID: 30576763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Mohr N; Vythilingum B; Emsley RA; Stein DJ
    Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder.
    Goddard AW; Shekhar A; Whiteman AF; McDougle CJ
    Drug Discov Today; 2008 Apr; 13(7-8):325-32. PubMed ID: 18405845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology.
    Agid O; Lerer B
    J Clin Psychiatry; 1999 Jan; 60(1):55-6. PubMed ID: 10074882
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological management of obsessive-compulsive disorder: a review for clinicians.
    McDonough M; Kennedy N
    Harv Rev Psychiatry; 2002; 10(3):127-37. PubMed ID: 12023928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.